As part of our comprehensive strategy for managing specialty drugs, Independence is proud to announce the establishment of our Advanced Network for Gene‑Based Therapeutics. This network ensures that our members have access to multi-million-dollar gene‑based therapies, like Luxturna®, Zolgensma®, and Skysona®, delivered in facilities that share our commitment to driving clinical outcomes and value. Click here for the full story.